(2)
|
Xxxxxxxx xxxxxxxx pro xxxxxxxx látky („xxxxxxxx“) xxxx v souladu x xxxxxxx 37 xxxxxxxx (ES) x. 1272/2008 předloženy návrhy xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx a xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx některých xxxxxx xxxxx. Na xxxxxxx xxxxxxxxxx&xxxx;(2) k xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („RAC“) xxxxxxxx, xxxxx i xxxxxxxxxx xxxxxxxxxxxx xxxxx, xx xxxxxx zavést, aktualizovat xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx a označení xxxxxxxxx látek. Xxxxxxx xxxxxxxxxx xxxxxx XXX xxxx:
—
|
xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxx dusičné... %[X ≤ 70 %],
|
—
|
xxxxxxxxxx xx dne 9. března 2018 xxxxxxx xxxxxx x xxxxxxx křemíku (x xxxxxxx < 3 μx,xxxxx &xx; 5 μx a xxxxxx xxxxx ≥ 3:1),
|
—
|
stanovisko xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,
|
—
|
xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx tris(2-methoxyethoxy)vinylsilanu, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,
|
—
|
xxxxxxxxxx ze dne 8. června 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,
|
—
|
xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně granulované xxxx,
|
—
|
xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],
|
—
|
xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxxx-xxxxxxxxx, [1] stannanu, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2],
|
—
|
xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx dibenzo[def,p]chrysenu, dibenzo[a,l]pyrenu,
|
—
|
stanovisko xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx (XXX), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 8. června 2018 ohledně xxxxxxxxxxxxxx (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,
|
—
|
xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx 2,2-bis(brommethyl)propan-1,3-diolu,
|
—
|
stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,
|
—
|
xxxxxxxxxx xx xxx 28. xxxxx 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (XXX), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, S-ethyl 4-chlor-o-tolyloxythioacetátu,
|
—
|
stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,
|
—
|
xxxxxxxxxx ze xxx 14. září 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,
|
—
|
xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx glyoxylové xxxxxxxx …%,
|
—
|
xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx natrium-N-(hydroxymethyl)glycinátu, [xxxxxxxxxxx xxxxxxxx z xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],
|
—
|
xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [K-HDO],
|
—
|
stanovisko xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],
|
—
|
xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx (2RS)-2-[4-(4-chlorfenoxy)-2(trifluoromethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-olu, xxxxxxxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,
|
—
|
xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (XXX),
|
—
|
xxxxxxxxxx ze xxx 30. listopadu 2018 ohledně 4,5-dichlor-2-oktyl-2H-isothiazol-3-onu, [XXXXX],
|
—
|
xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [MBIT],
|
—
|
stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],
|
—
|
xxxxxxxxxx xx xxx 15. října 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxxxxxx (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxx (XXX), N-allyl-4,5-dimethyl-2(trimethylsilyl)thiofen-3-karboxamidu,
|
—
|
stanovisko xx dne 9. xxxxxx 2018 ohledně xxxxxxx, xxxxxxx [xxxx xxxxxxxx za xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx],
|
—
|
xxxxxxxxxx xx xxx 8. června 2018 ohledně xxxxxxxx xxxxxxx …%[X&xx; 70 %],
|
—
|
xxxxxxxxxx x 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],
|
—
|
xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxx-xxxxxxx (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,
|
—
|
stanovisko ze 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],
|
—
|
xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxx,
|
—
|
xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,
|
—
|
xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,
|
—
|
xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,
|
—
|
stanovisko ze xxx 8. června 2018 xxxxxxx azoxystrobinu (XXX), xxxxxx (E)-2-{2-[6-(2-kyanofenoxy)pyrimidin-4-yloxy]fenyl}-3-methoxyakrylátu,
|
—
|
stanovisko xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],
|
—
|
xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx hymexazolu (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 30. listopadu 2018 ohledně hexythiazoxu (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,
|
—
|
stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,
|
—
|
xxxxxxxxxx ze xxx 9. března 2018 ohledně xxxxxxxxxxxx (XXX), xxxxxxx směsi: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,
|
—
|
stanovisko xx xxx 14. září 2018 xxxxxxx-xxxxx, ethylmethylketoximu, xxxxxxxxxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx ze dne 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,
|
—
|
xxxxxxxxxx ze xxx 9. xxxxxx 2018 ohledně rozvětveného xxxxxxxxxxxxxxx,
|
—
|
xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxx 2-(1-(diethylaminohydroxyfenyl) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(diethylamin)-2-hydroxybenzoyl]benzoátu.
|
|